DEXTROMETHORPHAN

US Approved OTC

First approved in 1954

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H25NO
Molecular Weight	271.3979
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1CC[C@]23CCCC[C@]3([H])[C@]1([H])Cc4ccc(cc42)OC

InChI

InChIKey=MKXZASYAUGDDCJ-NJAFHUGGSA-N

InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C18H25NO
Molecular Weight	271.3979
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27139517
Curator's Comment:: https://www.ncbi.nlm.nih.gov/pubmed/25420446

Dextromethorphan is a non-narcotic morphine derivative widely used as an antitussive for almost 40 years. It has attracted attention due to its anticonvulsant and neuroprotective properties. It is a cough suppressant in many over-the-counter cold and cough medicines. In 2010, the FDA approved the combination product dextromethorphan/quinidine for the treatment of pseudobulbar affect. Dextromethorphan suppresses the cough reflex by a direct action on the cough center in the medulla of the brain. Dextromethorphan shows high-affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist and acts as a non-competitive channel blocker. It is one of the widely used antitussives and is used to study the involvement of glutamate receptors in neurotoxicity. Dextromethorphan (DM) is a sigma-1 receptor agonist and an uncompetitive NMDA receptor antagonist. The mechanism by which dextromethorphan exerts therapeutic effects in patients with pseudobulbar affect is unknown. Dextromethorphan should not be taken with monoamine oxidase inhibitors due to the potential for serotonin syndrome. Dextromethorphan is extensively metabolized by CYP2D6 to dextrorphan, which is rapidly glucuronidated and unable to cross the blood-brain barrier.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sigma opioid receptor 60 Target ID: CHEMBL287 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15723099	Agonist 2456	Cough	205 nM [Ki]
Glutamate [NMDA] receptor subunit 3A 21 Target ID: CHEMBL4787 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2897648	Antagonist 2577	Cough

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cough 103 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21620_mucinex_lbl.pdf	Primary	Sigma opioid receptor Glutamate [NMDA] receptor subunit 3A	Approved 7997	MUCINEX DM Approved Use Helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive: temporarily relieves: cough due to minor throat and bronchial irritation as may occur with the common cold or inhaled irritants; the intensity of coughing; the impulse to cough to help you get to sleep Launch Date 1083196800000
Pseudobulbar affect 7 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26000221	Primary		Approved 7997	NUEDEXTA Approved Use NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurologic conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state. PBA is a specific condition, distinct from other types of emotional lability that may occur in patients with neurological disease or injury. Launch Date 1285804800000

C_max

Value	Dose	Co-administered	Analyte	Population
4.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
95.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE	QUINIDINE	DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
15.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE	QUINIDINE	DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
123.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE	QUINIDINE	DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
124.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE	QUINIDINE	DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
599 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
709 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
32 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
52 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1049 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE	QUINIDINE	DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
133.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE	QUINIDINE	DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
17.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1000.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE	QUINIDINE	DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
933.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE	QUINIDINE	DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2898 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3608 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
68 nM*h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01361217	30 mg single, oral dose: 30 mg route of administration: oral experiment type: single co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: healthy age: adults sex: food status:

T_1/2

Value	Dose	Co-administered	Analyte	Population
13.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE	QUINIDINE	DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
50 mg 4 times / day steady, oral Dose: 50 mg, 4 times / day Route: oral Route: steady Dose: 50 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8741125	unhealthy, 19-52 years Health Status: unhealthy Age Group: 19-52 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/8741125	Sources: https://pubmed.ncbi.nlm.nih.gov/8741125
960 mg 1 times / day multiple, oral Highest studied dose Dose: 960 mg, 1 times / day Route: oral Route: multiple Dose: 960 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2529964	unhealthy, 19-67 years Health Status: unhealthy Age Group: 19-67 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2529964	Sources: https://pubmed.ncbi.nlm.nih.gov/2529964
120 mg single, oral Recommended Dose: 120 mg Route: oral Route: single Dose: 120 mg Sources: https://pubmed.ncbi.nlm.nih.gov/26294136	healthy, 26.5 years Health Status: healthy Age Group: 26.5 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/26294136	Sources: https://pubmed.ncbi.nlm.nih.gov/26294136
900 mg single, oral Overdose Dose: 900 mg Route: oral Route: single Dose: 900 mg Sources: https://pubmed.ncbi.nlm.nih.gov/31033494	unknown, 27 years Health Status: unknown Age Group: 27 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/31033494	Other AEs: Ischemic colitis... Other AEs: Ischemic colitis (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/31033494
270 mg single, oral Overdose Dose: 270 mg Route: oral Route: single Dose: 270 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2018593	unknown, 3 years Health Status: unknown Age Group: 3 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/2018593	Other AEs: Lethargy, Ataxia... Other AEs: Lethargy (1 patient) Ataxia (1 patient) Nystagmus (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/2018593

AEs

AE	Significance	Dose	Population
Ischemic colitis	1 patient	900 mg single, oral Overdose Dose: 900 mg Route: oral Route: single Dose: 900 mg Sources: https://pubmed.ncbi.nlm.nih.gov/31033494	unknown, 27 years Health Status: unknown Age Group: 27 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/31033494
Ataxia	1 patient	270 mg single, oral Overdose Dose: 270 mg Route: oral Route: single Dose: 270 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2018593	unknown, 3 years Health Status: unknown Age Group: 3 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/2018593
Lethargy	1 patient	270 mg single, oral Overdose Dose: 270 mg Route: oral Route: single Dose: 270 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2018593	unknown, 3 years Health Status: unknown Age Group: 3 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/2018593
Nystagmus	1 patient	270 mg single, oral Overdose Dose: 270 mg Route: oral Route: single Dose: 270 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2018593	unknown, 3 years Health Status: unknown Age Group: 3 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/2018593

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1172 inducer 657	inhibitor 1318	substrate 1038 inhibitor 1421	inhibitor 1360

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1268 CYP2A6 594 CYP2B6 679 CYP2C8 761 CYP2C19 1215 CYP2E1 761	P-gp 1223	CYP1A2 618 CYP2B6 486

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1406	inducer 1333 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14	no
CYP1A2 1406	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14	no
CYP2A6 625	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14	no
CYP2B6 845	inducer 1333 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14	no
CYP2B6 845	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14	no
CYP2C19 1277	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14	no
CYP2C8 810	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14	no
CYP2C9 1362	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14	no
CYP2D6 1455	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14	no
CYP2E1 841	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14	no
CYP3A4 1462	inducer 1333 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14	no
CYP3A4 1462	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14	no

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1223	substrate 2752 Sources: https://www.eurekaselect.com/66423/article/lack-interaction-nmda-receptor-antagonists-dextromethorphan-and-dextrorphan-p	no
CYP2D6 1038	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/11602530/ Page: 2	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1392	inhibitor 1374 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021879Orig1s000OtherR.pdf#page=63 Page: 63

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:4470	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4470
ZINC	ZINC000003201907	http://zinc15.docking.org/substances/ZINC000003201907

PubMed

Title	Date	PubMed
Differential effects of morphinan drugs on haloperidol-induced catalepsy in rats: a comparative study with an N-methyl-D-aspartate antagonist.	1991 Mar-Apr	1685312
The need for rational therapeutics in the use of cough and cold medicine in infants.	1992 Apr	1557278
Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.	2004 Oct 26	15505150
Epigenetic silencing of DSC3 is a common event in human breast cancer.	2005	16168112
High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry.	2005	16124035
The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via sigma1 receptor activation: comparison with the effects of dextromethorphan.	2005 Apr	15723099
Characterization of microsomal cytochrome P450-dependent monooxygenases in the rat olfactory mucosa.	2005 Aug	15879494
Dextromethorphan psychosis, dependence and physical withdrawal.	2005 Dec	16318953
MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity.	2005 Jul 19	15987631
Evaluation of dextromethorphan metabolism using hepatocytes from CYP2D6 poor and extensive metabolizers.	2005 Jun	15988119
Cytochrome P450 2D6 (CYP2D6) inhibitory constituents of Catharanthus roseus.	2005 Jun	15930738
Dextromethorphan-induced delirium and possible methadone interaction.	2005 Mar	16089243
Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes.	2005 May	15863898
Recombinant production of human microsomal cytochrome P450 2D6 in the methylotrophic yeast Pichia pastoris.	2005 Nov	16222729
Side effects of dextromethorphan abuse, a case series.	2005 Sep	16122622
Dextromethorphan-induced neurologic illness in a patient with negative toxicology findings.	2006 Jun 27	16801672
Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.	2006 May	16634036
Mesenteric artery clamping/unclamping-induced acute lung injury is attenuated by N-methyl-D-aspartate antagonist dextromethorphan.	2006 Nov-Dec	17102908
Co-administration of dextromethorphan with methamphetamine attenuates methamphetamine-induced rewarding and behavioral sensitization.	2006 Sep	16865411
Bench-to-bedside review: mechanisms and management of hyperthermia due to toxicity.	2007	18096088
Cough mixture abuse as a novel cause of folate deficiency: a prospective, community-based, controlled study.	2007 Apr	17488670
Sex differences in the potency of kappa opioids and mixed-action opioids administered systemically and at the site of inflammation against capsaicin-induced hyperalgesia in rats.	2007 Apr	17225166
Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.	2007 Aug	17470523
Treatment of the common cold.	2007 Feb 15	17323712
A placebo double-blind pilot study of dextromethorphan for problematic behaviors in children with autism.	2007 Jan	17175572
Oral administration of dextromethorphan does not produce neuronal vacuolation in the rat brain.	2007 Jul	17573115
In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/MSMS run: analytical validation and testing with monoclonal anti-CYP antibodies.	2007 Jul	17565714
Free energies of binding of R- and S-propranolol to wild-type and F483A mutant cytochrome P450 2D6 from molecular dynamics simulations.	2007 Jul	17333164
[Simultaneous determination of the inhibitory potency of compounds on the activity of five cytochrome P-450 enzymes using a cocktail probe substrates method].	2007 Jun	17702393
Challenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewal.	2007 Jun 1	17543114
Validated method for rapid inhibition screening of six cytochrome P450 enzymes by liquid chromatography-tandem mass spectrometry.	2007 Jun 1	17267297
Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis.	2007 May 9	17418993
Effect of sodium ozagrel on the activity of rat CYP2D6.	2007 Nov 14	17651725
Dextromethorphan: a review of N-methyl-d-aspartate receptor antagonist in the management of pain.	2007 Spring	17461892
Ubiquitous computing for remote cardiac patient monitoring: a survey.	2008	18604301
Mechanical aspects of a multidirectional, angular stable osteosynthesis system and comparison with four conventional systems.	2008 Apr	18346904
Effects of common antitussive drugs on the hERG potassium channel current.	2008 Dec	19034038
Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias.	2008 Jan 8	18281903
Anti-inflammatory effects of dimemorfan on inflammatory cells and LPS-induced endotoxin shock in mice.	2008 Jul	18500357
Functional expression and comparative characterization of nine murine cytochromes P450 by fluorescent inhibition screening.	2008 Jul	18420780
Life-threatening dextromethorphan intoxication associated with interaction with amitriptyline in a poor CYP2D6 metabolizer: a single case re-exposure study.	2008 Jul	18359183
Effects of repeated cycles of sterilisation on the mechanical characteristics of titanium miniplates for osteosynthesis.	2008 Sep	18336967
Effect of fenofibrate on microcirculation and wound healing in healthy and diabetic mice.	2009	19258215
Dextromethorphan reduces oxidative stress and inhibits atherosclerosis and neointima formation in mice.	2009 Apr 1	19189960
The diagnostic role of glycosaminoglycans in pleural effusions: a pilot study.	2009 Feb 18	19226451
Amyotrophic lateral sclerosis.	2009 Feb 3	19192301
Characterization of retrieved orthodontic miniscrew implants.	2009 Jan	19121491
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.	2009 Jan	19029129
Retrospective analysis of titanium plate-retained prostheses placed after total rhinectomy.	2009 Jan-Feb	19344034
[Bone anchored hearing aids (BAHA)].	2009 Mar	19343390

Patents

Sample Use Guides

In Vivo Use Guide

15-30 mg 3 to 4 times per day (cough)

Route of Administration: Oral

In Vitro Use Guide

In vitro studies pre- and immature oligodendroglial (OLN-93) cells were subjected to hyperoxic conditions for 48 h after pre-treatment with increasing doses of dextromethorphan.

Substance Class	Chemical Created by `admin` on `Fri Jun 25 21:00:41 UTC 2021` Edited by `admin` on `Fri Jun 25 21:00:41 UTC 2021`
Record UNII	7355X3ROTS
Record Status	`Validated (UNII)`
Record Version

Download

Related Record	Type

Name

Type

Language

DEXTROMETHORPHAN

Official Name

English

BA-2666

Code

English

BA 2666

Common Name

English

DEX

Common Name

English

NSC-751452

Code

English

DEXTROMETHORPHAN [VANDF]

Common Name

English

NODEX

Common Name

English

DEXTROMETHORPHAN [MI]

Common Name

English

D-METHORPHAN

Common Name

English

DEXTROMETHORPHAN [WHO-DD]

Common Name

English

(+)-DEXTROMETHORPHAN

Common Name

English

DEXTROMETHORPHAN [USP MONOGRAPH]

Common Name

English

DEXTROMETHORPHAN [MART.]

Common Name

English

MORPHINAN, 3-METHOXY-17-METHYL-, (9.ALPHA.,13.ALPHA.,14.ALPHA.)-

Common Name

English

3-METHOXY-17-METHYL-9.ALPHA.,13.ALPHA.,14.ALPHA.-MORPHINAN

Common Name

English

DEXTROMETHORPHAN [HSDB]

Common Name

English

DEXTROMETHORPHAN [INN]

Common Name

English

DEXTROMETHORPHAN [USP-RS]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000181821